SMAD4 and cholangiocarcinoma: In cholangiocarcinoma, next-generation sequencing of 31 cholangiocarcinoma cases identified SMAD4 as a favourable prognostic biomarker in intrahepatic CCA and perihilar CCA by univariate and multivariate analysis.